<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nutr Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Nutr Sci</journal-id><journal-id journal-id-type="publisher-id">JNS</journal-id><journal-title-group><journal-title>Journal of Nutritional Science</journal-title></journal-title-group><issn pub-type="epub">2048-6790</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26090097</article-id><article-id pub-id-type="pmc">4463018</article-id><article-id pub-id-type="doi">10.1017/jns.2015.5</article-id><article-id pub-id-type="pii">S2048679015000051</article-id><article-id pub-id-type="publisher-id">00005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Oral administration of <italic>Bifidobacterium breve</italic> B-3 modifies
metabolic functions in adults with obese tendencies in a randomised controlled trial</article-title><alt-title alt-title-type="left-running">Jun-ichi Minami <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">Oral administration of <italic>Bifidobacterium
breve</italic> B-3 modifies metabolic functions</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Minami</surname><given-names>Jun-ichi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Kondo</surname><given-names>Shizuki</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yanagisawa</surname><given-names>Naotake</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Odamaki</surname><given-names>Toshitaka</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Jin-zhong</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abe</surname><given-names>Fumiaki</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nakajima</surname><given-names>Shigeru</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hamamoto</surname><given-names>Yukie</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Saitoh</surname><given-names>Sanae</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shimoda</surname><given-names>Taeko</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Food Science and Technology
Institute</institution>, <addr-line>Morinaga Milk Industry Co. Ltd</addr-line>,
<addr-line>Zama</addr-line>, <addr-line>Kanagawa</addr-line>, <country>Japan</country></aff><aff id="aff2"><label>2</label><institution>Nutritional Science Institute</institution>,
<addr-line>Morinaga Milk Industry Co. Ltd</addr-line>, <addr-line>Zama</addr-line>,
<addr-line>Kanagawa</addr-line>, <country>Japan</country></aff><aff id="aff3"><label>3</label><institution>NAKAJIMA Medical Clinic</institution>,
<addr-line>Yokosuka</addr-line>, <addr-line>Kanagawa</addr-line>, <country>Japan</country></aff><aff id="aff4"><label>4</label><addr-line>Division of Healthcare Graduate School</addr-line>,
<institution>Tokyo Healthcare University</institution>, <addr-line>Setagaya</addr-line>,
<addr-line>Tokyo</addr-line>, <country>Japan</country></aff><author-notes><corresp id="cor1"><label>*</label><addr-line><bold>Corresponding author:</bold> Dr Jun-ichi
Minami</addr-line>, email <email>j-minami@morinagamilk.co.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>5</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e17</elocation-id><history><date date-type="received"><day>01</day><month>4</month><year>2014</year></date><date date-type="rev-recd"><day>05</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>), which permits
unrestricted re-use, distribution, and reproduction in any medium, provided the original
work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S2048679015000051a.pdf"/><abstract abstract-type="normal"><p>Accumulating evidence suggests an association between gut microbiota and the development
of obesity, raising the possibility of probiotic administration as a therapeutic approach.
<italic>Bifidobacterium breve</italic> B-3 was found to exhibit an anti-obesity effect
on high-fat diet-induced obesity mice. In the present study, a randomised, double-blind,
placebo-controlled trial was conducted to evaluate the effect of the consumption of
<italic>B. breve</italic> B-3 on body compositions and blood parameters in adults with a
tendency for obesity. After a 4-week run-in period, the participants were randomised to
receive either placebo or a B-3 capsule (approximately 5 &#x000d7; 10<sup>10</sup> colony-forming
units of B-3/d) daily for 12 weeks. A significantly lowered fat mass was observed in the
B-3 group compared with the placebo group at week 12. Improvements were observed for some
blood parameters related to liver functions and inflammation, such as
&#x003b3;-glutamyltranspeptidase and high-sensitivity C-reactive protein. Significant correlations
were found between the changed values of some blood parameters and the changed fat mass in
the B-3 group. These results suggest the beneficial potential of <italic>B. breve</italic>
B-3 in improving metabolic disorders.</p></abstract><kwd-group><title>Key words</title><kwd><italic>Bifidobacterium</italic></kwd><kwd>Metabolic syndrome</kwd><kwd>Obesity</kwd><kwd>Randomised controlled trials</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><kwd>DIO, diet-induced obesity
</kwd><kwd>&#x003b3;-GTP, &#x003b3;-glutamyltranspeptidase
</kwd><kwd>HbA1c, glycated Hb
</kwd><kwd>hCRP, high-sensitivity C-reactive
protein
</kwd><kwd>LPS, lipopolysaccharide
</kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><ref-count count="46"/><page-count count="25"/></counts></article-meta></front><body><p>Obesity is becoming a global epidemic and a major contributor to the increased incidence of
serious chronic diseases, such as type 2 diabetes, CVD, hepatic and skeletal muscle insulin
resistance, and certain types of cancer<sup>(</sup><xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref><sup>)</sup>. The main cause of obesity is an imbalance between energy intake and
expenditure. However, there is a growing body of evidence that not only energy intake and
expenditure habits explain the increasing prevalence of obesity; environmental factors
contribute as well<sup>(</sup><xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref><sup>)</sup>.</p><p>Even within monozygotic twins, some individuals are more prone to weight gain, suggesting
that factors other than the human genome are involved in the development of
obesity<sup>(</sup><xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref><sup>)</sup>. The gut microbiota is an example of an environmental factor that may
affect the development of obesity. Recent evidence suggests that the gut microbiota has a
supporting function in regulating energy balance, fat storage, neurohormonal functions and
immune systems<sup>(</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>&#x02013;</sup><xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref><sup>)</sup>. Accordingly, recent studies have suggested that manipulating the
composition of the microbial ecosystem in the gut may be a novel approach in the treatment of
obesity. Such treatment might consist of altering the composition of the microbial communities
of an obese individual by administering beneficial micro-organisms, commonly known as
probiotics<sup>(</sup><xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref><sup>)</sup>.</p><p>In the context of obesity, several studies have reported that a low number of
<italic>Bifidobacterium</italic> spp. is correlated with the development of obesity and/or
diabetes<sup>(</sup><xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref><sup>&#x02013;</sup><xref rid="ref10" ref-type="bibr">
<sup>10</sup>
</xref><sup>)</sup>. Furthermore, Cani <italic>et al.</italic><sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>,</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>)</sup> demonstrated that diet-induced obesity (DIO) (high-fat&#x02013;low-carbohydrate
diet) in mice markedly affects the gut microbial community, in which the levels of
<italic>Bifidobacterium</italic> spp. were significantly reduced, in agreement with
observations in human subjects. Ilmonen <italic>et al.</italic><sup>(</sup><xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref><sup>)</sup> applied <italic>Lactobacillus rhamnosus</italic> together with
<italic>Bifidobacterium lactis</italic> Bb12 to prevent obesity during and after pregnancy,
which resulted in reduced body weight. Mikirova <italic>et al.</italic><sup>(</sup><xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref><sup>)</sup> found that a probiotic combination of both <italic>L. acidophilus</italic>
and <italic>B. bifidum</italic> reduced body weight among fifty-three obese individuals. A
double-blind randomised controlled trial by Kadooka <italic>et al.</italic><sup>(</sup><xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref><sup>)</sup> demonstrated that the administration of the microbial strain
<italic>Lactobacillus gasseri</italic> SBT2055 reduced adiposity and body weight. The
authors also demonstrated the reproducible effect of SBT2055 to lower the visceral fat mass,
BMI, and waist and hip circumferences by a randomised controlled trial using fermented milk
with a lower concentration of <italic>L. gasseri</italic> SBT2055.</p><p>Along with the evidence of the therapeutic effects of probiotic bacteria against obesity,
some mechanisms of action have been proposed, such as an effect on appetite regulation, host
metabolism, the inhibition of lipid absorption, the maintenance of intestinal homeostasis and
integrity, and low-grade inflammation<sup>(</sup><xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref><sup>&#x02013;</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>)</sup>. However, the effects of these probiotic bacteria are believed to be
strain dependent, and the underlying mechanism remains unclear<sup>(</sup><xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref><sup>)</sup>. To establish a therapeutic approach by which the administration of
probiotic bacteria can prevent obesity, further research for each bacterial strain is
necessary.</p><p>We previously reported that the administration of a probiotic strain <italic>B.
breve</italic> B-3 in a mouse model of DIO reduced body-weight gain and visceral fat deposits
in a dose-dependent manner and improved the serum levels of total cholesterol, glucose and
insulin<sup>(</sup><xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref><sup>)</sup>. However, the effect of this strain on human subjects has not yet been
investigated.</p><p>Here, we conducted a randomised, double-blind, parallel-group comparative study to examine
whether the consumption of a capsule containing live <italic>B. breve</italic> B-3 effects
body composition and blood parameters in adults with a tendency for obesity.</p><sec sec-type="methods" id="sec1"><title>Subjects and methods</title><sec id="sec1-1"><title>Trial design</title><p>The present study was designed as a randomised, double-blind, parallel-group comparative
study. The protocol was in accordance with the Declaration of Helsinki. All of the
participants provided written informed consent. All of the study protocols were approved
and controlled by the Ethics Committee of Tokyo Healthcare University (Tokyo Japan). The
study was performed from January to June 2012 at the Nakajima medical clinic in Kanagawa
Prefecture, Japan.</p></sec><sec id="sec1-2" sec-type="subjects"><title>Participants</title><p>A total of fifty-two adult volunteers were recruited based on their BMI (ranging from 24
to 30 kg/m<sup>2</sup>) and age (ranging from 40 to 69 years) at the Nakajima medical
clinic. Most of the participants were under clinical practice for diabetes including
nutrition education and medication. The exclusion criteria included regular ingestion of
diet foods or supplements for lowering body fat or cholesterol (more than twice per week),
ingestion of products with probiotic bacteria that could affect the microbiota as an
intestinal regulator, a history of severe diseases of the liver, kidney, heart, lung,
digestive organs, blood, endocrine system or metabolic pathway, and the presence of a food
allergy or drug allergy. A flowchart of participants is shown in <xref ref-type="fig" rid="fig01">Fig. 1</xref>. <fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Participant flowchart. B-3, <italic>Bifidobacterium breve</italic> B-3.</p></caption><graphic xlink:href="S2048679015000051_fig1"/></fig></p></sec><sec id="sec1-3"><title>Procedure</title><p>The study period consisted of a 4-week run-in period, followed by a 12-week ingestion
period. Initially, during the run-in period, the participants were instructed to complete
a questionnaire of body measurements, lifestyle habits (intake of yogurt, smoking and
alcohol drinking), disorders, allergies and regular medications. Each subject made a daily
record of their alcohol drinking, exercise and activities, usage of drugs, defecation and
physical condition. For the body composition and blood test, the baseline measurement took
place at the end of the 4-week run-in period, which was regarded as week 0. After the
run-in period, the participants were stratified by sex and BMI (above 27 or less than 27
kg/m<sup>2</sup>) and randomly divided into two groups according to computer-generated
permuted-block randomisation at Tokyo Healthcare University. Each group was then
randomised to receive three capsules of placebo capsule or B-3 capsule daily for 12 weeks.
During the study, the participants were advised not to change their regular lifestyles,
including their diet, exercise and regular medications. Then, the subjects initiated the
intake of B-3 or the placebo capsule and visited the clinic to receive physical
measurements, blood sampling and a medical interview every 4 weeks, i.e. at 4, 8 and 12
weeks after the initiation of capsule intake.</p></sec><sec id="sec1-4"><title>Test samples</title><p>The capsules of B-3 contained lyophilised powder of <italic>B. breve</italic> B-3, a
strain originating from a healthy infant, and had mainly maize starch as the carrier in an
acid-protective gelatin capsule. The placebo capsule only included an internal matrix
(mainly maize starch). We confirmed that the B-3 capsules contained approximately 5 &#x000d7;
10<sup>10</sup> colony-forming units per three capsules by microbial colony count using
reinforced clostridial agar (Oxoid) before the clinical trial. The B-3 and placebo
capsules appeared and tasted identical.</p></sec><sec id="sec1-5"><title>Outcomes</title><p>Changes in body composition (body weight, BMI, muscle mass, fat mass, fat percentage,
waist:hip ratio) and blood parameters (blood lipids, blood glucose, liver function,
inflammatory parameters) at 12 weeks were the primary and secondary outcomes,
respectively. Body weight, muscle mass and body fat (amount and percentage) were measured
by the bioelectrical impedance method using the medical-grade measurement device InBody3.0
(Takumi). BMI was calculated as body weight (kg)/height (m<xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref>). The waist:hip ratio was calculated based on the waist circumference and hip
circumference. Blood analysis was performed at Health Science Research Institute Co., Ltd
(Tokyo, Japan).</p></sec><sec id="sec1-6"><title>Statistical analysis</title><p>SAS software version 9.3 (SAS Institute, Inc.) was used for statistical analyses.
Variables that did not follow a normal distribution were analysed after natural log
transformation. For clarity, the values are presented according to the original scale in
the tables. The baseline characteristics were compared with a Fisher's exact test for
categorical variables and a two-sample <italic>t</italic> test for continuous variables.
For the primary and secondary outcomes, a comparison at 12 weeks was performed between the
experimental groups using ANCOVA adjusted for the baseline (week 0). The within-group
change at each time point (weeks 4, 8 and 12) from the baseline (week 0) was analysed
using a one-sample <italic>t</italic> test. The correlation between the changing values in
the fat mass and those of the other parameters between 0 and 12 weeks were analysed using
Pearson's correlation, followed by standardising each variable (<italic>z</italic> score).
A <italic>P</italic> value &#x0003c;0&#x000b7;05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec2"><title>Results</title><sec id="sec2-1"><title>Baseline characteristics of participants</title><p>Of the participants, four in the B-3 group and two in the placebo group withdrew from the
intervention due to personal reasons. One individual in each group reported a serious
change of lifestyle (being on a diet by dietary restriction) during the test period;
therefore, these participants were removed from the analysis. Thus, the final datasets for
the present study were nineteen for the B-3 group and twenty-five for the placebo group
(<xref ref-type="fig" rid="fig01">Fig. 1</xref>). The baseline values of the subject
demographics, physical characteristics, prescribed drug usage (for diabetes mellitus,
hyperlipidaemia and hypertension) and metabolic markers (TAG, fasting blood sugar and
HDL-cholesterol) did not differ significantly between the B-3 and placebo groups (<xref ref-type="table" rid="tab01">Table 1</xref>). Compliance was high for sample ingestion:
98&#x000b7;4 (<sc>sem</sc> 2&#x000b7;6) and 102&#x000b7;5 (<sc>sem</sc> 2&#x000b7;2) % in the B-3 and placebo groups,
respectively. <table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics of the subjects</p><p>(Mean values with their standard errors or number or percentage of
participants)</p></caption><alternatives><graphic xlink:href="S2048679015000051_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="right" width="1*" span="1"/><col align="right" width="1*" span="1"/><col align="right" width="1*" span="1"/><col align="right" width="1*" span="1"/><col align="right" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Group&#x02026;</th><th align="center" colspan="2" rowspan="1">Placebo</th><th align="center" colspan="2" rowspan="1"><italic>Bifidobacterium
breve</italic> B-3</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>*</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex (<italic>n</italic>)</td><td align="center" colspan="2" rowspan="1">25</td><td align="center" colspan="2" rowspan="1">19</td><td rowspan="1" colspan="1">0&#x000b7;535</td></tr><tr><td rowspan="1" colspan="1">Male</td><td align="center" colspan="2" rowspan="1">11</td><td align="center" colspan="2" rowspan="1">6</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female</td><td align="center" colspan="2" rowspan="1">14</td><td align="center" colspan="2" rowspan="1">13</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">61&#x000b7;9</td><td align="char" char="." rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">58&#x000b7;9</td><td align="char" char="." rowspan="1" colspan="1">2&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;302</td></tr><tr><td rowspan="1" colspan="1">Body weight (kg)</td><td rowspan="1" colspan="1">71&#x000b7;2</td><td align="char" char="." rowspan="1" colspan="1">2&#x000b7;3</td><td rowspan="1" colspan="1">68&#x000b7;9</td><td align="char" char="." rowspan="1" colspan="1">2&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;506</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">27&#x000b7;7</td><td align="char" char="." rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">27&#x000b7;1</td><td align="char" char="." rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;461</td></tr><tr><td rowspan="1" colspan="1">Muscle mass (kg)</td><td rowspan="1" colspan="1">45&#x000b7;1</td><td align="char" char="." rowspan="1" colspan="1">2&#x000b7;0</td><td rowspan="1" colspan="1">44&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;908</td></tr><tr><td rowspan="1" colspan="1">Fat mass (kg)</td><td rowspan="1" colspan="1">23&#x000b7;5</td><td align="center" rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">21&#x000b7;5</td><td align="char" char="." rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;187</td></tr><tr><td rowspan="1" colspan="1">Fat percentage (%)</td><td rowspan="1" colspan="1">33&#x000b7;3</td><td align="center" rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">31&#x000b7;3</td><td align="char" char="." rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;276</td></tr><tr><td colspan="6" rowspan="1">Prescribed drug use (%)</td></tr><tr><td rowspan="1" colspan="1">For diabetes mellitus</td><td align="center" colspan="2" rowspan="1">72</td><td align="center" colspan="2" rowspan="1">79</td><td rowspan="1" colspan="1">0&#x000b7;734</td></tr><tr><td rowspan="1" colspan="1">For hyperlipidaemia</td><td align="center" colspan="2" rowspan="1">52</td><td align="center" colspan="2" rowspan="1">68</td><td rowspan="1" colspan="1">0&#x000b7;358</td></tr><tr><td rowspan="1" colspan="1">For hypertension</td><td align="center" colspan="2" rowspan="1">36</td><td align="center" colspan="2" rowspan="1">42</td><td rowspan="1" colspan="1">0&#x000b7;760</td></tr><tr><td colspan="6" rowspan="1">Metabolic markers (%)</td></tr><tr><td rowspan="1" colspan="1">TAG &#x02265; 1&#x000b7;7 mmol/l&#x02020;</td><td align="center" colspan="2" rowspan="1">60</td><td align="center" colspan="2" rowspan="1">42</td><td rowspan="1" colspan="1">0&#x000b7;361</td></tr><tr><td rowspan="1" colspan="1">Fasting blood sugar &#x02265; 6&#x000b7;1 mmol/l&#x02020;</td><td align="center" colspan="2" rowspan="1">84</td><td align="center" colspan="2" rowspan="1">79</td><td rowspan="1" colspan="1">0&#x000b7;709</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol &#x0003c; 1&#x000b7;0 mmol/l&#x02020;</td><td align="center" colspan="2" rowspan="1">4</td><td align="center" colspan="2" rowspan="1">5</td><td rowspan="1" colspan="1">1&#x000b7;000</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>* <italic>P</italic> values of Fisher's exact test for categorical data and
<italic>P</italic> values of two-sample <italic>t</italic> tests for continuous
data are shown.</p></fn><fn><p>&#x02020; Proportion of participants with a baseline level higher than the borderline for
domestic criteria of the metabolic syndrome in Japan.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2-2"><title>Effect on body composition</title><p><xref ref-type="table" rid="tab02">Table 2</xref> shows the transition of each body
composition during the intervention. As a primary outcome, the changes in body composition
at 12 weeks were analysed by ANCOVA. A significantly lowered fat mass was observed in the
B-3 group compared with the placebo group. A tendency for an inter-group difference was
observed for the fat percentage, but there was no significant difference for the other
parameters between the two groups. During the intervention, a significant decrease from
the baseline (week 0) was observed for body weight (weeks 4 and 12 for the B-3 group; week
4 for the placebo group), BMI (week 4 for both groups), fat mass (weeks 4 and 12 for the
B-3 group), fat percentage (week 12 for the B-3 group) and waist:hip ratio (weeks 8 and 12
for both groups). <table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Changes in physical examination values</p><p>(Mean values with their standard errors)</p></caption><alternatives><graphic xlink:href="S2048679015000051_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Group&#x02026;</th><th align="center" colspan="8" rowspan="1">Placebo</th><th align="center" colspan="8" rowspan="1"><italic>Bifidobacterium
breve</italic> B-3</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Week 0</th><th align="center" colspan="2" rowspan="1">Week 4</th><th align="center" colspan="2" rowspan="1">Week 8</th><th align="center" colspan="2" rowspan="1">Week 12</th><th align="center" colspan="2" rowspan="1">Week 0</th><th align="center" colspan="2" rowspan="1">Week 4</th><th align="center" colspan="2" rowspan="1">Week 8</th><th align="center" colspan="2" rowspan="1">Week 12</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Body weight (kg)</td><td rowspan="1" colspan="1">71&#x000b7;2</td><td rowspan="1" colspan="1">2&#x000b7;3</td><td rowspan="1" colspan="1">70&#x000b7;4*</td><td rowspan="1" colspan="1">2&#x000b7;3</td><td rowspan="1" colspan="1">71&#x000b7;0</td><td rowspan="1" colspan="1">2&#x000b7;3</td><td rowspan="1" colspan="1">70&#x000b7;8</td><td rowspan="1" colspan="1">2&#x000b7;3</td><td rowspan="1" colspan="1">68&#x000b7;9</td><td rowspan="1" colspan="1">2&#x000b7;7</td><td rowspan="1" colspan="1">68&#x000b7;4*</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">68&#x000b7;6</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">69&#x000b7;1*</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;493</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">27&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">27&#x000b7;5*</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">27&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">27&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">27&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">26&#x000b7;9*</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">27&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">27&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;403</td></tr><tr><td rowspan="1" colspan="1">Muscle mass (kg)</td><td rowspan="1" colspan="1">45&#x000b7;1</td><td rowspan="1" colspan="1">2&#x000b7;0</td><td rowspan="1" colspan="1">44&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">44&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">44&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">44&#x000b7;8</td><td rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">44&#x000b7;8</td><td rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">44&#x000b7;9</td><td rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">45&#x000b7;7</td><td rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;376</td></tr><tr><td rowspan="1" colspan="1">Fat mass (kg)</td><td rowspan="1" colspan="1">23&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">23&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">23&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">23&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">21&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">21&#x000b7;0*</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">21&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">20&#x000b7;8**</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;046</td></tr><tr><td rowspan="1" colspan="1">Fat percentage (%)</td><td rowspan="1" colspan="1">33&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">33&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">33&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">33&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;2</td><td rowspan="1" colspan="1">31&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">30&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">30&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">30&#x000b7;3*</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;066</td></tr><tr><td rowspan="1" colspan="1">Waist:hip ratio</td><td rowspan="1" colspan="1">0&#x000b7;964</td><td rowspan="1" colspan="1">0&#x000b7;0084</td><td rowspan="1" colspan="1">0&#x000b7;960</td><td rowspan="1" colspan="1">0&#x000b7;0086</td><td rowspan="1" colspan="1">0&#x000b7;958*</td><td rowspan="1" colspan="1">0&#x000b7;0085</td><td rowspan="1" colspan="1">0&#x000b7;963*</td><td rowspan="1" colspan="1">0&#x000b7;0076</td><td rowspan="1" colspan="1">0&#x000b7;935</td><td rowspan="1" colspan="1">0&#x000b7;0091</td><td rowspan="1" colspan="1">0&#x000b7;932</td><td rowspan="1" colspan="1">0&#x000b7;0084</td><td rowspan="1" colspan="1">0&#x000b7;928**</td><td rowspan="1" colspan="1">0&#x000b7;0081</td><td rowspan="1" colspan="1">0&#x000b7;931**</td><td rowspan="1" colspan="1">0&#x000b7;0071</td><td rowspan="1" colspan="1">0&#x000b7;174</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Mean value within a group was significantly different from that at baseline (week
0): * <italic>P</italic> &#x0003c; 0&#x000b7;05, ** <italic>P</italic> &#x0003c; 0&#x000b7;01
(one-sample <italic>t</italic> test).</p></fn><fn><p>&#x02020; Differences between the placebo and B-3 groups at week 12 were analysed by
ANCOVA, adjusted for baseline (week 0).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2-3"><title>Effect of <italic>Bifidobacterium breve</italic> B-3 on blood parameters</title><p><xref ref-type="table" rid="tab03">Table 3</xref> shows the transition of blood
parameters during the intervention. Significant inter-group differences were observed for
the values of &#x003b3;-glutamyltranspeptidase (&#x003b3;-GTP) (<italic>P</italic> = 0&#x000b7;011) and
high-sensitivity C-reactive protein (hCRP) (<italic>P</italic> = 0&#x000b7;039) at week 12. No
significant difference was observed for blood lipids (total, LDL- and HDL-cholesterol,
TAG) (data not shown). During the intervention, significant increases from the baseline
(week 0) were observed for glycated Hb (HbA1c) (weeks 4 and 8 for both groups, week 12 for
the placebo group), &#x003b3;-GTP (week 12 for the placebo group) and total bilirubin (weeks 4 and
8 for the placebo group). Significant decreases from the baseline were observed for
insulin (weeks 4 and 8 for the placebo group), alkaline phosphatase (ALP) (week 8 for the
B-3 group) and hCRP (week 12 for the B-3 group). <table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Changes in blood parameters</p><p>(Mean values with their standard errors)</p></caption><alternatives><graphic xlink:href="S2048679015000051_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Group&#x02026;</th><th align="center" colspan="8" rowspan="1">Placebo</th><th align="center" colspan="8" rowspan="1"><italic>Bifidobacterium
breve</italic> B-3</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Week 0</th><th align="center" colspan="2" rowspan="1">Week 4</th><th align="center" colspan="2" rowspan="1">Week 8</th><th align="center" colspan="2" rowspan="1">Week 12</th><th align="center" colspan="2" rowspan="1">Week 0</th><th align="center" colspan="2" rowspan="1">Week 4</th><th align="center" colspan="2" rowspan="1">Week 8</th><th align="center" colspan="2" rowspan="1">Week 12</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Fasting blood glucose (mmol/l)&#x02021;</td><td rowspan="1" colspan="1">8&#x000b7;63</td><td rowspan="1" colspan="1">0&#x000b7;72</td><td rowspan="1" colspan="1">9&#x000b7;03</td><td rowspan="1" colspan="1">1&#x000b7;00</td><td rowspan="1" colspan="1">8&#x000b7;51</td><td rowspan="1" colspan="1">0&#x000b7;88</td><td rowspan="1" colspan="1">8&#x000b7;60</td><td rowspan="1" colspan="1">0&#x000b7;74</td><td rowspan="1" colspan="1">9&#x000b7;88</td><td rowspan="1" colspan="1">0&#x000b7;90</td><td rowspan="1" colspan="1">10&#x000b7;16</td><td rowspan="1" colspan="1">0&#x000b7;83</td><td rowspan="1" colspan="1">9&#x000b7;39</td><td rowspan="1" colspan="1">0&#x000b7;66</td><td rowspan="1" colspan="1">9&#x000b7;83</td><td rowspan="1" colspan="1">0&#x000b7;71</td><td rowspan="1" colspan="1">0&#x000b7;541</td></tr><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td rowspan="1" colspan="1">7&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">7&#x000b7;2*</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">7&#x000b7;2*</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">7&#x000b7;3*</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">7&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">7&#x000b7;8*</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">7&#x000b7;8*</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">7&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;249</td></tr><tr><td rowspan="1" colspan="1">Glycoalbumin (%)</td><td rowspan="1" colspan="1">18&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">18&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">18&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">19&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">21&#x000b7;0</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">20&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">20&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">20&#x000b7;3</td><td rowspan="1" colspan="1">3&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;213</td></tr><tr><td rowspan="1" colspan="1">1,5-Anyhdroglucitol (&#x000b5;g/ml)</td><td rowspan="1" colspan="1">9&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">10&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">10&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">10&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">6&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">6&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;725</td></tr><tr><td rowspan="1" colspan="1">Insulin (&#x000b5;U/ml)&#x02021;&#x000a7;</td><td rowspan="1" colspan="1">39&#x000b7;9</td><td rowspan="1" colspan="1">10&#x000b7;3</td><td rowspan="1" colspan="1">31&#x000b7;8*</td><td rowspan="1" colspan="1">8&#x000b7;9</td><td rowspan="1" colspan="1">29&#x000b7;1*</td><td rowspan="1" colspan="1">8&#x000b7;6</td><td rowspan="1" colspan="1">39&#x000b7;4</td><td rowspan="1" colspan="1">12&#x000b7;7</td><td rowspan="1" colspan="1">32&#x000b7;0</td><td rowspan="1" colspan="1">6&#x000b7;1</td><td rowspan="1" colspan="1">25&#x000b7;5</td><td rowspan="1" colspan="1">4&#x000b7;3</td><td rowspan="1" colspan="1">25&#x000b7;9</td><td rowspan="1" colspan="1">5&#x000b7;4</td><td rowspan="1" colspan="1">37&#x000b7;7</td><td rowspan="1" colspan="1">8&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;096</td></tr><tr><td rowspan="1" colspan="1">AST (IU/l)&#x02021;</td><td rowspan="1" colspan="1">26&#x000b7;4</td><td rowspan="1" colspan="1">3&#x000b7;0</td><td rowspan="1" colspan="1">26&#x000b7;6</td><td rowspan="1" colspan="1">2&#x000b7;5</td><td rowspan="1" colspan="1">26&#x000b7;8</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">27&#x000b7;2</td><td rowspan="1" colspan="1">3&#x000b7;3</td><td rowspan="1" colspan="1">29&#x000b7;7</td><td rowspan="1" colspan="1">5&#x000b7;4</td><td rowspan="1" colspan="1">28&#x000b7;9</td><td rowspan="1" colspan="1">4&#x000b7;5</td><td rowspan="1" colspan="1">27&#x000b7;9</td><td rowspan="1" colspan="1">4&#x000b7;7</td><td rowspan="1" colspan="1">29&#x000b7;5</td><td rowspan="1" colspan="1">5&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;624</td></tr><tr><td rowspan="1" colspan="1">ALT (IU/l)&#x02021;</td><td rowspan="1" colspan="1">28&#x000b7;6</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">29&#x000b7;7</td><td rowspan="1" colspan="1">3&#x000b7;1</td><td rowspan="1" colspan="1">30&#x000b7;2</td><td rowspan="1" colspan="1">3&#x000b7;2</td><td rowspan="1" colspan="1">30&#x000b7;6</td><td rowspan="1" colspan="1">3&#x000b7;1</td><td rowspan="1" colspan="1">34&#x000b7;0</td><td rowspan="1" colspan="1">5&#x000b7;3</td><td rowspan="1" colspan="1">35&#x000b7;1</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">34&#x000b7;2</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">32&#x000b7;2</td><td rowspan="1" colspan="1">4&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;156</td></tr><tr><td rowspan="1" colspan="1">ALP (IU/l)&#x02021;</td><td rowspan="1" colspan="1">209&#x000b7;5</td><td rowspan="1" colspan="1">12&#x000b7;3</td><td rowspan="1" colspan="1">211&#x000b7;9</td><td rowspan="1" colspan="1">13&#x000b7;9</td><td rowspan="1" colspan="1">203&#x000b7;5</td><td rowspan="1" colspan="1">12&#x000b7;5</td><td rowspan="1" colspan="1">207&#x000b7;2</td><td rowspan="1" colspan="1">12&#x000b7;0</td><td rowspan="1" colspan="1">242&#x000b7;7</td><td rowspan="1" colspan="1">20&#x000b7;0</td><td rowspan="1" colspan="1">241&#x000b7;7</td><td rowspan="1" colspan="1">20&#x000b7;1</td><td rowspan="1" colspan="1">230&#x000b7;2*</td><td rowspan="1" colspan="1">18&#x000b7;0</td><td rowspan="1" colspan="1">234&#x000b7;3</td><td rowspan="1" colspan="1">18&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;704</td></tr><tr><td rowspan="1" colspan="1">Lactate dehydrogenase (IU/l)</td><td rowspan="1" colspan="1">199&#x000b7;0</td><td rowspan="1" colspan="1">7&#x000b7;9</td><td rowspan="1" colspan="1">197&#x000b7;1</td><td rowspan="1" colspan="1">7&#x000b7;2</td><td rowspan="1" colspan="1">197&#x000b7;8</td><td rowspan="1" colspan="1">7&#x000b7;8</td><td rowspan="1" colspan="1">199&#x000b7;4</td><td rowspan="1" colspan="1">8&#x000b7;5</td><td rowspan="1" colspan="1">197&#x000b7;4</td><td rowspan="1" colspan="1">6&#x000b7;6</td><td rowspan="1" colspan="1">197&#x000b7;6</td><td rowspan="1" colspan="1">8&#x000b7;3</td><td rowspan="1" colspan="1">196&#x000b7;2</td><td rowspan="1" colspan="1">8&#x000b7;6</td><td rowspan="1" colspan="1">197&#x000b7;2</td><td rowspan="1" colspan="1">8&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;936</td></tr><tr><td rowspan="1" colspan="1">&#x003b3;-GTP (IU/l)&#x02021;</td><td rowspan="1" colspan="1">39&#x000b7;0</td><td rowspan="1" colspan="1">6&#x000b7;1</td><td rowspan="1" colspan="1">39&#x000b7;6</td><td rowspan="1" colspan="1">7&#x000b7;0</td><td rowspan="1" colspan="1">42&#x000b7;4</td><td rowspan="1" colspan="1">8&#x000b7;1</td><td rowspan="1" colspan="1">44&#x000b7;0*</td><td rowspan="1" colspan="1">8&#x000b7;4</td><td rowspan="1" colspan="1">37&#x000b7;0</td><td rowspan="1" colspan="1">7&#x000b7;1</td><td rowspan="1" colspan="1">41&#x000b7;7</td><td rowspan="1" colspan="1">8&#x000b7;1</td><td rowspan="1" colspan="1">39&#x000b7;6</td><td rowspan="1" colspan="1">8&#x000b7;2</td><td rowspan="1" colspan="1">37&#x000b7;8</td><td rowspan="1" colspan="1">7&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;011</td></tr><tr><td rowspan="1" colspan="1">Total bilirubin (&#x000b5;mol/l)&#x02021;</td><td rowspan="1" colspan="1">8&#x000b7;90</td><td rowspan="1" colspan="1">0&#x000b7;51</td><td rowspan="1" colspan="1">11&#x000b7;12*</td><td rowspan="1" colspan="1">0&#x000b7;68</td><td rowspan="1" colspan="1">10&#x000b7;60*</td><td rowspan="1" colspan="1">0&#x000b7;68</td><td rowspan="1" colspan="1">10&#x000b7;09</td><td rowspan="1" colspan="1">0&#x000b7;68</td><td rowspan="1" colspan="1">10&#x000b7;43</td><td rowspan="1" colspan="1">0&#x000b7;86</td><td rowspan="1" colspan="1">10&#x000b7;77</td><td rowspan="1" colspan="1">0&#x000b7;86</td><td rowspan="1" colspan="1">10&#x000b7;09</td><td rowspan="1" colspan="1">0&#x000b7;86</td><td rowspan="1" colspan="1">10&#x000b7;43</td><td rowspan="1" colspan="1">0&#x000b7;86</td><td rowspan="1" colspan="1">0&#x000b7;233</td></tr><tr><td rowspan="1" colspan="1">hCRP (mg/l)&#x02021;</td><td rowspan="1" colspan="1">0&#x000b7;88</td><td rowspan="1" colspan="1">0&#x000b7;14</td><td rowspan="1" colspan="1">0&#x000b7;90</td><td rowspan="1" colspan="1">0&#x000b7;19</td><td rowspan="1" colspan="1">0&#x000b7;93</td><td rowspan="1" colspan="1">0&#x000b7;18</td><td rowspan="1" colspan="1">1&#x000b7;10</td><td rowspan="1" colspan="1">0&#x000b7;18</td><td rowspan="1" colspan="1">0&#x000b7;98</td><td rowspan="1" colspan="1">0&#x000b7;25</td><td rowspan="1" colspan="1">1&#x000b7;27</td><td rowspan="1" colspan="1">0&#x000b7;32</td><td rowspan="1" colspan="1">1&#x000b7;05</td><td rowspan="1" colspan="1">0&#x000b7;23</td><td rowspan="1" colspan="1">0&#x000b7;90*</td><td rowspan="1" colspan="1">0&#x000b7;27</td><td rowspan="1" colspan="1">0&#x000b7;039</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>HbA1c, glycated Hb; AST, aspartate transaminase; ALT, alanine aminotransferase;
ALP, alkaline phosphatase; &#x003b3;-GTP, &#x003b3;-glutamyltranspeptidase; hCRP, high-sensitivity
C-reactive protein.</p></fn><fn><p>* Mean value within a group was significantly different from that at baseline
(week 0) (<italic>P</italic> &#x0003c; 0&#x000b7;05; one-sample <italic>t</italic>
test).</p></fn><fn><p>&#x02020; Differences between the placebo and B-3 groups at week 12 were analysed by
ANCOVA, adjusted for baseline (week 0).</p></fn><fn><p>&#x02021; Analysis for within-group and intergroup differences was performed after
logarithmic transformation of the values.</p></fn><fn><p>&#x000a7; To convert insulin in &#x000b5;U/ml to pmol/l, multiply by 6&#x000b7;945.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2-4"><title>Correlation of changes in body fat mass with blood parameters</title><p>Significant positive correlations were found between the changed values of the body fat
mass and those of alanine aminotransferase (ALT) and &#x003b3;-GTP; negative correlations were
found with 1,5-anhydroglucitol in the B-3 group but not in the placebo group (<xref ref-type="fig" rid="fig02">Fig. 2</xref>). No significant correlation was found between
the changed values of the body fat mass and those of other blood parameters. <fig id="fig02" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Correlation analysis between changed values at week 12 from week 0 of body fat mass
and blood parameters: (a) &#x003b3;-glutamyltranspeptidase (&#x003b3;-GTP); (b) alanine
aminotransferase (ALT); (c) 1,5-anhydroglucitol (1,5-AG) by Pearson's correlation
test. Data shown are correlation coefficients (&#x003c1;) with <italic>P</italic> values. *
<italic>P</italic> &#x0003c; 0&#x000b7;05. For ALT and &#x003b3;-GTP, correlation analysis was
performed using the data after logarithmic transformation and standardisation.
(&#x02013;&#x02013;&#x02013;&#x02013;, &#x025cf;), <italic>Bifidobacterium breve</italic> B-3 (B-3) group; (----, &#x025cb;),
placebo group.</p></caption><graphic xlink:href="S2048679015000051_fig2"/></fig></p></sec></sec><sec sec-type="discussion" id="sec3"><title>Discussion</title><p>We conducted this clinical trial to examine whether the intake of capsules containing a
single strain of live <italic>B. breve</italic> B-3 could influence the obese tendencies of
adults. In the present study, the B-3 group did not show a significant reduction in body
weight compared with the placebo group; however, the fat mass was significantly reduced by
the intake of capsules containing probiotic <italic>B. breve</italic> B-3 for 12 weeks. The
decreased fat mass was 0&#x000b7;7 kg on average after 12 weeks in the B-3 group. Similar results
were observed by Kadooka <italic>et al</italic>.<sup>(</sup><xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref><sup>)</sup>, who showed an average of 0&#x000b7;6 kg reduction in body fat mass after a
12-week ingestion of a <italic>Lactobacillus</italic> strain, <italic>L. gasseri</italic>
SBT2055. Although strict diet restriction may induce a dramatic change in fat mass (for
example, &#x02212;12&#x000b7;4 kg after intake of 2090 kJ (500 kcal)/d for 5 weeks), such a serious diet
programme may be accompanied by the risk of a rebound effect due to the declined muscle mass
and lowered basal metabolism. Also there would be concerns about the difficulty in
continuation. There is considerable evidence that visceral fat obesity is a key aetiological
factor for the development of metabolic syndromes, and the excess accumulation of visceral
fat is primarily involved in metabolic disorders<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>,</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>)</sup>. The present results suggest the potential of <italic>B. breve</italic>
B-3 in the prevention of chronic diseases triggered by adiposity in a sustainable way. Since
the intervention was only 12 weeks, future study is needed to evaluate the long-term effects
of <italic>B. breve</italic> B-3 ingestion.</p><p>In the present study, the participants were recruited at a medical clinic, and most of them
were under clinical practice for diabetes. <xref ref-type="table" rid="tab01">Table 1</xref>
shows that there was no difference in drug usage between the two groups. In addition, these
regular medications were not changed during the intervention. Some participants were
prescribed sulfonylureas (56 % in the placebo group and 53 % in the B-3 group) and
thiazolidinediones (24 % in the placebo group and 16 % in the B-3 group), diabetes mellitus
drugs which have been suggested to affect body weight<sup>(</sup><xref rid="ref23" ref-type="bibr">
<sup>23</sup>
</xref><sup>)</sup>; however, there was no significant difference between the two groups.
Since most of the participants were under clinical practice for diabetes including nutrition
education and medication, the values with relation to diabetes such as fasting blood
glucose, HbA1c, glycoalbumin and insulin tended to be higher than the normal levels at
baseline (<xref ref-type="table" rid="tab01">Tables 1</xref> and <xref ref-type="table" rid="tab03">3</xref>). No significant improvement was found in these parameters by B-3
intake as compared with the placebo group during the intervention; however, there was a
tendency of improvement for the values of glycoalbumin, a parameter known to reflect the
most recent blood glucose status, in the B-3 group (<italic>P</italic> = 0&#x000b7;081 at week 12)
(<xref ref-type="table" rid="tab03">Table 3</xref>). In addition, there were significant
increases in the levels of HbA1c, a parameter known to reflect blood glucose levels for the
previous 2&#x02013;3 months, during the intervention in the placebo group, but this was disappeared
in the B-3 group at week 12 (<xref ref-type="table" rid="tab03">Table 3</xref>).
Interestingly, there was a significant negative correlation between the changed values of
fat mass and 1,5-anhydroglucitol, a parameter known to closely reflect diabetic control
within several days, in the B-3 group but not the placebo group at week 12 (<xref ref-type="fig" rid="fig02">Fig. 2</xref>). These results suggest the potential of B-3 in
the improvement of diabetes, although further investigation with long-term treatment is
needed.</p><p>In the present study, we also observed a significant improvement in &#x003b3;-GTP, which correlated
with the reduction of fat mass during the consumption period. The correlation between serum
&#x003b3;-GTP levels and risk of the metabolic syndrome has been indicated in large-scale
investigations performed in Korea and Japan<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>,</sup><xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref><sup>)</sup>. Clinically, evaluations of serum &#x003b3;-GTP levels are widely used as
markers to evaluate the degree of liver injury<sup>(</sup><xref rid="ref26" ref-type="bibr">
<sup>26</sup>
</xref><sup>,</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>)</sup>. In addition, &#x003b3;-GTP has been used as a marker of hepatobiliary tract
function and excessive alcohol consumption<sup>(</sup><xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref><sup>&#x02013;</sup><xref rid="ref30" ref-type="bibr">
<sup>30</sup>
</xref><sup>)</sup>. A stronger correlation between serum &#x003b3;-GTP level and metabolic syndrome
risk factors was observed in a non-drinker subgroup compared with all other study
subjects<sup>(</sup><xref rid="ref31" ref-type="bibr">
<sup>31</sup>
</xref><sup>)</sup>. Aller <italic>et al.</italic><sup>(</sup><xref rid="ref32" ref-type="bibr">
<sup>32</sup>
</xref><sup>)</sup> reported that the administration of a tablet of 500 million
<italic>Lactobacillus bulgaricus</italic> and <italic>Streptococcus thermophilus</italic>
improved liver aminotransferases levels in patients with non-alcoholic fatty liver disease.
In a pilot study, short-term oral supplementation with <italic>Bifidobacterium
bifidum</italic> and <italic>Lactobacillus plantarum</italic> 8PA3 was associated with an
improvement in alcohol-induced liver injury compared with standard therapy
alone<sup>(</sup><xref rid="ref33" ref-type="bibr">
<sup>33</sup>
</xref><sup>)</sup>; however, the effect of probiotics in the improvement of &#x003b3;-GTP has not
be previously evaluated. Although the mechanism of probiotics in the improvement of liver
function has not yet been adequately evaluated, the results observed in the present study
are in agreement with our previous experimental result showing that feeding DIO mice
<italic>B. breve</italic> B-3 led to the regulated gene expression of pathways involved in
lipid metabolism, as well as responses to stress in the liver<sup>(</sup><xref rid="ref34" ref-type="bibr">
<sup>34</sup>
</xref><sup>)</sup>.</p><p>Accumulating evidence indicates that obesity is associated with a state of chronic,
low-grade inflammation, suggesting that inflammation may be a potential mechanism by which
obesity leads to insulin resistance<sup>(</sup><xref rid="ref35" ref-type="bibr">
<sup>35</sup>
</xref><sup>&#x02013;</sup><xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref><sup>)</sup>. In the early stages of obesity, adipocytes become hypertrophied in
response to overnutrition. With increasing adiposity, adipose tissue releases signals such
as monocyte chemoattractant protein-1, causing increased monocyte influx<sup>(</sup><xref rid="ref39" ref-type="bibr">
<sup>39</sup>
</xref><sup>)</sup>. In the advanced stages of obesity, various types of immune cells, such
as macrophages, infiltrate into obese adipose tissue and thus enhance the inflammatory
changes through cross-talk with adipose tissue-released NEFA<sup>(</sup><xref rid="ref40" ref-type="bibr">
<sup>40</sup>
</xref><sup>,</sup><xref rid="ref41" ref-type="bibr">
<sup>41</sup>
</xref><sup>)</sup>. Lipopolysaccharides (LPS) have been suggested to be involved in the
development of metabolic syndromes associated with high fat intake<sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>,</sup><xref rid="ref42" ref-type="bibr">
<sup>42</sup>
</xref><sup>,</sup><xref rid="ref43" ref-type="bibr">
<sup>43</sup>
</xref><sup>)</sup>. These reports described that mice fed on a high-fat diet for 2 to 4
weeks exhibited a significant increase in plasma LPS. This increase in plasma LPS induced by
a high-fat diet suggests metabolic endotoxaemia, which is considered to trigger the
development of obesity, inflammation, insulin resistance, type 2 diabetes and
atherosclerosis via activation of the CD14/Toll-like receptor 4 complex by LPS and/or fatty
acids. However, supplementation with oligofructose stimulates bifidobacterial growth and
lowers the uptake of LPS from the gut lumen<sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>)</sup>. This effect is also correlated with an improved glucose tolerance and
insulin sensitivity. Hoarau <italic>et al.</italic><sup>(</sup><xref rid="ref44" ref-type="bibr">
<sup>44</sup>
</xref><sup>)</sup> reported that the supernatant fraction of <italic>B. breve</italic> C50
can induce prolonged dendritic cell survival, with oppositional action on the
maturation&#x02013;apoptosis programme induced by LPS. The <italic>B. breve</italic> supernatant
fraction alone was reported to be a poor cytokine inducer but may have immunomodulatory
properties<sup>(</sup><xref rid="ref45" ref-type="bibr">
<sup>45</sup>
</xref><sup>)</sup>. Jeon <italic>et al.</italic><sup>(</sup><xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref><sup>)</sup> found that <italic>B. breve</italic> but not <italic>L. casei</italic>
induced the development of IL-10-producing Tr1 cells in the large intestine, which
demonstrates that <italic>B. breve</italic> prevents intestinal inflammation. In the present
study, the 12-week intake of <italic>B. breve</italic> B-3 resulted in significantly
decreased hCRP levels compared with the placebo group (<xref ref-type="table" rid="tab03">Table 3</xref>). In our previous study, we observed the down-regulation of the expression
of acute-phase proteins, such as <italic>Saa</italic> and <italic>Orm</italic>, by
administering <italic>B. breve</italic> B-3 to DIO mice, together with the suppression of
body-weight gain and fat accumulation<sup>(</sup><xref rid="ref34" ref-type="bibr">
<sup>34</sup>
</xref><sup>)</sup>. These results suggest that <italic>B. breve</italic> B-3 may function
in suppressing the pro-inflammatory reaction related to obesity.</p><p>In summary, the 12-week intake of the probiotic <italic>B. breve</italic> B-3 reduced the
fat mass of adult subjects with obese tendencies. Possible improvement was also observed for
liver function and the systemic inflammatory reaction by <italic>B. breve</italic> B-3
administration. No serious adverse events were observed by medical interview or measurements
of blood parameters. <italic>B. breve</italic> B-3 is capable of producing SCFA, such as
acetic acid and lactic acid, and other bioactive components, such as conjugated linoleic
acid and other fatty acid metabolites, which are possibly involved in the anti-metabolic
syndrome effect. A further large-scale randomised controlled trial is needed to confirm the
clinical effect of <italic>B. breve</italic> B-3 on improving metabolic function. A study is
underway to identify the active components of <italic>B. breve</italic> B-3 involved in the
anti-metabolic syndrome effect.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are grateful to the patients of Nakajima clinic who participated in the present study.</p><p>There was no funding for the present study.</p><p>S. K., J.-Z. X., and T. S. were responsible for the study design. S. N. and Y. H. carried
out the study. N. Y. and J.-Z. X carried out the statistical analysis. J. M. and
J.<bold>-</bold>Z. X wrote the manuscript. T. O., F. A., S. S. and T. S. reviewed and
approved the final manuscript.</p><p>The authors declare no conflict of interest.</p></ack><ref-list id="reflist1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Haslam</surname><given-names>DW</given-names></name> &#x00026; <name><surname>James</surname><given-names>WPT</given-names></name> (<year>2005</year>) <article-title>Obesity</article-title>. <source>Lancet</source>
<volume>366</volume>, <fpage>1197</fpage>&#x02013;<lpage>1209</lpage>.<pub-id pub-id-type="pmid">16198769</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Mekkes</surname><given-names>MC</given-names></name>, <name><surname>Weenen</surname><given-names>TC</given-names></name>, <name><surname>Brummer</surname><given-names>RJ</given-names></name>, <etal/> (<year>2013</year>) <article-title>The development of probiotic treatment
in obesity: a review</article-title>. <source>Benef Microbes</source>
<volume>5</volume>, <fpage>19</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">23886977</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Turnbaugh</surname><given-names>PJ</given-names></name>, <name><surname>Hamady</surname><given-names>M</given-names></name>, <name><surname>Yatsunenko</surname><given-names>T</given-names></name>, <etal/> (<year>2009</year>) <article-title>A core gut microbiome in obese and
lean twins</article-title>. <source>Nature</source>
<volume>457</volume>, <fpage>480</fpage>&#x02013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">19043404</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>DiBaise</surname><given-names>JK</given-names></name>, <name><surname>Zuccolo</surname><given-names>A</given-names></name>, <etal/> (<year>2009</year>) <article-title>Human gut microbiota in obesity and
after gastric bypass</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>106</volume>, <fpage>2365</fpage>&#x02013;<lpage>2370</lpage>.<pub-id pub-id-type="pmid">19164560</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Ley</surname><given-names>RE</given-names></name>, <name><surname>Turnbaugh</surname><given-names>PJ</given-names></name>, <name><surname>Klein</surname><given-names>S</given-names></name>, <etal/> (<year>2006</year>) <article-title>Microbial ecology: human gut microbes
associated with obesity</article-title>. <source>Nature</source>
<volume>444</volume>, <fpage>1022</fpage>&#x02013;<lpage>1023</lpage>.<pub-id pub-id-type="pmid">17183309</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Esteve</surname><given-names>E</given-names></name>, <name><surname>Ricart</surname><given-names>W</given-names></name> &#x00026; <name><surname>Fern&#x000e1;ndez-Real</surname><given-names>JM</given-names></name> (<year>2011</year>) <article-title>Gut microbiota interactions with obesity,
insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin
resistance?</article-title>
<source>Curr Opin Clin Nutr Metab Care</source>
<volume>14</volume>, <fpage>483</fpage>&#x02013;<lpage>490</lpage>.<pub-id pub-id-type="pmid">21681087</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Musso</surname><given-names>G</given-names></name>, <name><surname>Gambino</surname><given-names>R</given-names></name> &#x00026; <name><surname>Cassader</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Obesity, diabetes, and gut microbiota: the
hygiene hypothesis expanded?</article-title>
<source>Diabetes Care</source>
<volume>33</volume>, <fpage>2277</fpage>&#x02013;<lpage>2284</lpage>.<pub-id pub-id-type="pmid">20876708</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Kalliom&#x000e4;ki</surname><given-names>M</given-names></name>, <name><surname>Collado</surname><given-names>MC</given-names></name>, <name><surname>Salminen</surname><given-names>S</given-names></name>, <etal/> (<year>2008</year>) <article-title>Early differences in fecal microbiota
composition in children may predict overweight</article-title>. <source>Am J Clin Nutr</source>
<volume>87</volume>, <fpage>534</fpage>&#x02013;<lpage>538</lpage>.<pub-id pub-id-type="pmid">18326589</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Collado</surname><given-names>MC</given-names></name>, <name><surname>Isolauri</surname><given-names>E</given-names></name>, <name><surname>Laitinen</surname><given-names>K</given-names></name>, <etal/> (<year>2008</year>) <article-title>Distinct composition of gut microbiota
during pregnancy in overweight and normal-weight women</article-title>. <source>Am J
Clin Nutr</source>
<volume>88</volume>, <fpage>894</fpage>&#x02013;<lpage>899</lpage>.<pub-id pub-id-type="pmid">18842773</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>X</given-names></name>, <name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Han</surname><given-names>L</given-names></name>, <etal/> (<year>2010</year>) <article-title>Molecular characterisation of the
faecal microbiota in patients with type II diabetes</article-title>. <source>Curr
Microbiol</source>
<volume>61</volume>, <fpage>69</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">20087741</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Cani</surname><given-names>PD</given-names></name>, <name><surname>Neyrinck</surname><given-names>AM</given-names></name>, <name><surname>Fava</surname><given-names>F</given-names></name>, <etal/> (<year>2007</year>) <article-title>Selective increases of bifidobacteria
in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism
associated with endotoxaemia</article-title>. <source>Diabetologia</source>
<volume>50</volume>, <fpage>2374</fpage>&#x02013;<lpage>2383</lpage>.<pub-id pub-id-type="pmid">17823788</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Cani</surname><given-names>PD</given-names></name>, <name><surname>Amar</surname><given-names>J</given-names></name>, <name><surname>Iglesias</surname><given-names>MA</given-names></name>, <etal/> (<year>2007</year>) <article-title>Metabolic endotoxemia initiates
obesity and insulin resistance</article-title>. <source>Diabetes</source>
<volume>56</volume>, <fpage>1761</fpage>&#x02013;<lpage>1772</lpage>.<pub-id pub-id-type="pmid">17456850</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Ilmonen</surname><given-names>J</given-names></name>, <name><surname>Isolauri</surname><given-names>E</given-names></name>, <name><surname>Poussa</surname><given-names>T</given-names></name>, <etal/> (<year>2011</year>) <article-title>Impact of dietary counselling and
probiotic intervention on maternal anthropometric measurements during and after
pregnancy: a randomized placebo-controlled trial</article-title>. <source>Clin Nutr</source>
<volume>30</volume>, <fpage>156</fpage>&#x02013;<lpage>164</lpage>.<pub-id pub-id-type="pmid">20970896</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Mikirova</surname><given-names>NA</given-names></name>, <name><surname>Casciari</surname><given-names>JJ</given-names></name>, <name><surname>Hunninghake</surname><given-names>RE</given-names></name>, <etal/> (<year>2011</year>) <article-title>Effect of weight reduction on
cardiovascular risk factors and CD34-positive cells in circulation</article-title>.
<source>Int J Med Sci</source>
<volume>8</volume>, <fpage>445</fpage>&#x02013;<lpage>452</lpage>.<pub-id pub-id-type="pmid">21850193</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Kadooka</surname><given-names>Y</given-names></name>, <name><surname>Sato</surname><given-names>M</given-names></name>, <name><surname>Ogawa</surname><given-names>A</given-names></name>, <etal/> (<year>2013</year>) <article-title>Effect of <italic>Lactobacillus
gasseri</italic> SBT2055 in fermented milk on abdominal adiposity in adults in a
randomised controlled trial</article-title>. <source>Br J Nutr</source>
<volume>110</volume>, <fpage>1696</fpage>&#x02013;<lpage>1703</lpage>.<pub-id pub-id-type="pmid">23614897</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Sanz</surname><given-names>Y</given-names></name>, <name><surname>Santacruz</surname><given-names>A</given-names></name> &#x00026; <name><surname>Gauffin</surname><given-names>P</given-names></name> (<year>2010</year>) <article-title>Gut microbiota in obesity and metabolic
disorders</article-title>. <source>Proc Nutr Soc</source>
<volume>69</volume>, <fpage>434</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="pmid">20540826</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Kadooka</surname><given-names>Y</given-names></name>, <name><surname>Sato</surname><given-names>M</given-names></name>, <name><surname>Imaizumi</surname><given-names>K</given-names></name>, <etal/> (<year>2010</year>) <article-title>Regulation of abdominal adiposity by
probiotics (<italic>Lactobacillus gasseri</italic> SBT2055) in adults with obese
tendencies in a randomized controlled trial</article-title>. <source>Eur J Clin Nutr</source>
<volume>64</volume>, <fpage>636</fpage>&#x02013;<lpage>643</lpage>.<pub-id pub-id-type="pmid">20216555</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Delzenne</surname><given-names>NM</given-names></name>, <name><surname>Neyrinck</surname><given-names>AM</given-names></name> &#x00026; <name><surname>Cani</surname><given-names>PD</given-names></name> (<year>2013</year>) <article-title>Gut microbiota and metabolic disorders: how
prebiotic can work?</article-title>
<source>Br J Nutr</source>
<volume>109</volume>, <fpage>S81</fpage>&#x02013;<lpage>S85</lpage>.<pub-id pub-id-type="pmid">23360884</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Yin</surname><given-names>YN</given-names></name>, <name><surname>Yu</surname><given-names>QF</given-names></name>, <name><surname>Fu</surname><given-names>N</given-names></name>, <etal/> (<year>2010</year>) <article-title>Effects of four bifidobacteria on
obesity in high-fat diet induced rats</article-title>. <source>World J Gastroenterol</source>
<volume>16</volume>, <fpage>3394</fpage>&#x02013;<lpage>3401</lpage>.<pub-id pub-id-type="pmid">20632441</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Kondo</surname><given-names>S</given-names></name>, <name><surname>Xiao</surname><given-names>JZ</given-names></name>, <name><surname>Satoh</surname><given-names>T</given-names></name>, <etal/> (<year>2010</year>) <article-title>Antiobesity effects of
<italic>Bifidobacterium breve</italic> strain B-3 supplementation in a mouse model
with high-fat diet-induced obesity</article-title>. <source>Biosci Biotechnol Biochem</source>
<volume>74</volume>, <fpage>1656</fpage>&#x02013;<lpage>1661</lpage>.<pub-id pub-id-type="pmid">20699581</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Montague</surname><given-names>CT</given-names></name> &#x00026; <name><surname>O'Rahilly</surname><given-names>S</given-names></name> (<year>2000</year>) <article-title>The perils of portliness: causes and
consequences of visceral adiposity</article-title>. <source>Diabetes</source>
<volume>49</volume>, <fpage>883</fpage>&#x02013;<lpage>888</lpage>.<pub-id pub-id-type="pmid">10866038</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Fox</surname><given-names>CS</given-names></name>, <name><surname>Massaro</surname><given-names>JM</given-names></name>, <name><surname>Hoffmann</surname><given-names>U</given-names></name>, <etal/> (<year>2007</year>) <article-title>Abdominal visceral and subcutaneous
adipose tissue compartments: association with metabolic risk factors in the Framingham
Heart Study</article-title>. <source>Circulation</source>
<volume>116</volume>, <fpage>39</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">17576866</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Bennett</surname><given-names>WL</given-names></name>, <name><surname>Maruthur</surname><given-names>NM</given-names></name>, <name><surname>Singh</surname><given-names>S</given-names></name>, <etal/> (<year>2011</year>) <article-title>Comparative effectiveness and safety
of medications for type 2 diabetes: an update including new drugs and 2-drug
combinations</article-title>. <source>Ann Intern Med</source>
<volume>154</volume>, <fpage>602</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">21403054</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Nakanishi</surname><given-names>N</given-names></name>, <name><surname>Suzuki</surname><given-names>K</given-names></name> &#x00026; <name><surname>Tatara</surname><given-names>K</given-names></name> (<year>2004</year>) <article-title>Serum &#x003b3;-glutamyltransferase and risk of
metabolic syndrome and type 2 diabetes in middle-aged Japanese men</article-title>.
<source>Diabetes Care</source>
<volume>27</volume>, <fpage>1427</fpage>&#x02013;<lpage>1432</lpage>.<pub-id pub-id-type="pmid">15161799</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JH</given-names></name>, <name><surname>Um</surname><given-names>MH</given-names></name> &#x00026; <name><surname>Park</surname><given-names>YK</given-names></name> (<year>2013</year>) <article-title>The association of metabolic syndrome and serum
&#x003b3;-glutamyl transpeptidase: a 4-year cohort study of 3,698 Korean male
workers</article-title>. <source>Clin Nutr Res</source>
<volume>2</volume>, <fpage>67</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">23429457</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Lieber</surname><given-names>CS</given-names></name> (<year>1984</year>) <article-title>Alcohol and the liver: 1984
update</article-title>. <source>Hepatology</source>
<volume>4</volume>, <fpage>1243</fpage>&#x02013;<lpage>1260</lpage>.<pub-id pub-id-type="pmid">6389304</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Sato</surname><given-names>KK</given-names></name>, <name><surname>Hayashi</surname><given-names>T</given-names></name>, <name><surname>Nakamura</surname><given-names>Y</given-names></name>, <etal/> (<year>2008</year>) <article-title>Liver enzymes compared with alcohol
consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare
Study</article-title>. <source>Diabetes Care</source>
<volume>31</volume>, <fpage>1230</fpage>&#x02013;<lpage>1236</lpage>.<pub-id pub-id-type="pmid">18316395</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>PM</given-names></name>, <name><surname>Anton</surname><given-names>RF</given-names></name>, <name><surname>Egan</surname><given-names>BM</given-names></name>, <etal/> (<year>2005</year>) <article-title>Excessive alcohol consumption and
hypertension: clinical implications of current research</article-title>. <source>J Clin
Hypertens (Greenwich)</source>
<volume>7</volume>, <fpage>346</fpage>&#x02013;<lpage>351</lpage>.<pub-id pub-id-type="pmid">16088298</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>DH</given-names></name>, <name><surname>Ha</surname><given-names>MH</given-names></name>, <name><surname>Kim</surname><given-names>JH</given-names></name>, <etal/> (<year>2003</year>) <article-title>&#x003b3;-Glutamyltransferase and diabetes &#x02013; a
4 year follow-up study</article-title>. <source>Diabetologia</source>
<volume>46</volume>, <fpage>359</fpage>&#x02013;<lpage>364</lpage>.<pub-id pub-id-type="pmid">12687334</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>DH</given-names></name>, <name><surname>Silventoinen</surname><given-names>K</given-names></name>, <name><surname>Jacobs</surname><given-names>DR</given-names></name>, <etal/> (<year>2004</year>) <article-title>&#x003b3;-Glutamyltransferase, obesity, and
the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and
women</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>89</volume>, <fpage>5410</fpage>&#x02013;<lpage>5414</lpage>.<pub-id pub-id-type="pmid">15531490</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Fraser</surname><given-names>A</given-names></name>, <name><surname>Harris</surname><given-names>R</given-names></name>, <name><surname>Sattar</surname><given-names>N</given-names></name>, <etal/> (<year>2007</year>) <article-title>&#x003b3;-Glutamyltransferase is associated
with incident vascular events independently of alcohol intake: analysis of the British
Women's Heart and Health Study and Meta-Analysis</article-title>. <source>Arterioscler
Thromb Vasc Biol</source>
<volume>27</volume>, <fpage>2729</fpage>&#x02013;<lpage>2735</lpage>.<pub-id pub-id-type="pmid">17932318</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Aller</surname><given-names>R</given-names></name>, <name><surname>De Luis</surname><given-names>DA</given-names></name>, <name><surname>Izaola</surname><given-names>O</given-names></name>, <etal/> (<year>2011</year>) <article-title>Effect of a probiotic on liver
aminotransferases in nonalcoholic fatty liver disease patients: a double blind
randomized clinical trial</article-title>. <source>Eur Rev Med Pharmacol Sci</source>
<volume>15</volume>, <fpage>1090</fpage>&#x02013;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">22013734</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Kirpich</surname><given-names>IA</given-names></name>, <name><surname>Solovieva</surname><given-names>NV</given-names></name>, <name><surname>Leikhter</surname><given-names>SN</given-names></name>, <etal/> (<year>2008</year>) <article-title>Probiotics restore bowel flora and
improve liver enzymes in human alcohol-induced liver injury: a pilot
study</article-title>. <source>Alcohol</source>
<volume>42</volume>, <fpage>675</fpage>&#x02013;<lpage>682</lpage>.<pub-id pub-id-type="pmid">19038698</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Kondo</surname><given-names>S</given-names></name>, <name><surname>Kamei</surname><given-names>A</given-names></name>, <name><surname>Xiao</surname><given-names>JZ</given-names></name>, <etal/> (<year>2013</year>) <article-title><italic>Bifidobacterium breve</italic>
B-3 exerts metabolic syndrome-suppressing effects in the liver of diet-induced obese
mice: a DNA microarray analysis</article-title>. <source>Benef Microbes</source>
<volume>4</volume>, <fpage>247</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">23666099</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>RG</given-names></name>, <name><surname>Hayden</surname><given-names>MS</given-names></name> &#x00026; <name><surname>Ghosh</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>NF-&#x003ba;B, inflammation, and metabolic
disease</article-title>. <source>Cell Metab</source>
<volume>13</volume>, <fpage>11</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">21195345</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Schenk</surname><given-names>S</given-names></name>, <name><surname>Saberi</surname><given-names>M</given-names></name> &#x00026; <name><surname>Olefsky</surname><given-names>JM</given-names></name> (<year>2008</year>) <article-title>Insulin sensitivity: modulation by nutrients
and inflammation</article-title>. <source>J Clin Invest</source>
<volume>118</volume>, <fpage>2992</fpage>&#x02013;<lpage>3002</lpage>.<pub-id pub-id-type="pmid">18769626</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Hotamisligil</surname><given-names>GS</given-names></name> &#x00026; <name><surname>Erbay</surname><given-names>E</given-names></name> (<year>2008</year>) <article-title>Nutrient sensing and inflammation in metabolic
diseases</article-title>. <source>Nat Rev Immunol</source>
<volume>8</volume>, <fpage>923</fpage>&#x02013;<lpage>934</lpage>.<pub-id pub-id-type="pmid">19029988</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Rocha</surname><given-names>VZ</given-names></name> &#x00026; <name><surname>Folco</surname><given-names>EJ</given-names></name> (<year>2011</year>) <article-title>Inflammatory concepts of
obesity</article-title>. <source>Int J Inflam</source>
<volume>2011</volume>, <fpage>529061</fpage>.<pub-id pub-id-type="pmid">21837268</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Weisberg</surname><given-names>SP</given-names></name>, <name><surname>McCann</surname><given-names>D</given-names></name>, <name><surname>Desai</surname><given-names>M</given-names></name>, <etal/> (<year>2003</year>) <article-title>Obesity is associated with macrophage
accumulation in adipose tissue</article-title>. <source>J Clin Invest</source>
<volume>112</volume>, <fpage>1796</fpage>&#x02013;<lpage>1808</lpage>.<pub-id pub-id-type="pmid">14679176</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Suganami</surname><given-names>T</given-names></name> &#x00026; <name><surname>Ogawa</surname><given-names>Y</given-names></name> (<year>2010</year>) <article-title>Adipose tissue macrophages: their role in
adipose tissue remodeling</article-title>. <source>J Leukoc Biol</source>
<volume>88</volume>, <fpage>33</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">20360405</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Suganami</surname><given-names>T</given-names></name>, <name><surname>Nishida</surname><given-names>J</given-names></name> &#x00026; <name><surname>Ogawa</surname><given-names>Y</given-names></name> (<year>2005</year>) <article-title>A paracrine loop between adipocytes and
macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis
factor &#x003b1;</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<volume>25</volume>, <fpage>2062</fpage>&#x02013;<lpage>2068</lpage>.<pub-id pub-id-type="pmid">16123319</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Cani</surname><given-names>PD</given-names></name>, <name><surname>Bibiloni</surname><given-names>R</given-names></name>, <name><surname>Knauf</surname><given-names>C</given-names></name>, <etal/> (<year>2008</year>) <article-title>Changes in gut microbiota control
metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes
in mice</article-title>. <source>Diabetes</source>
<volume>57</volume>, <fpage>1470</fpage>&#x02013;<lpage>1481</lpage>.<pub-id pub-id-type="pmid">18305141</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Cani</surname><given-names>PD</given-names></name>, <name><surname>Possemiers</surname><given-names>S</given-names></name>, <name><surname>Van de Wiele</surname><given-names>T</given-names></name>, <etal/> (<year>2009</year>) <article-title>Changes in gut microbiota control
inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut
permeability</article-title>. <source>Gut</source>
<volume>58</volume>, <fpage>1091</fpage>&#x02013;<lpage>1103</lpage>.<pub-id pub-id-type="pmid">19240062</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Hoarau</surname><given-names>C</given-names></name>, <name><surname>Lagaraine</surname><given-names>C</given-names></name>, <name><surname>Martin</surname><given-names>L</given-names></name>, <etal/> (<year>2006</year>) <article-title>Supernatant of <italic>Bifidobacterium
breve</italic> induces dendritic cell maturation, activation, and survival through a
Toll-like receptor 2 pathway</article-title>. <source>J Allergy Clin Immunol</source>
<volume>117</volume>, <fpage>696</fpage>&#x02013;<lpage>702</lpage>.<pub-id pub-id-type="pmid">16522473</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Bermudez-Brito</surname><given-names>M</given-names></name>, <name><surname>Mu&#x000f1;oz-Quezada</surname><given-names>S</given-names></name>, <name><surname>Gomez-Llorente</surname><given-names>C</given-names></name>, <etal/> (<year>2013</year>) <article-title>Cell-free culture supernatant of
<italic>Bifidobacterium breve</italic> CNCM I-4035 decreases pro-inflammatory
cytokines in human dendritic cells challenged with <italic>Salmonella typhi</italic>
through TLR activation</article-title>. <source>PLOS ONE</source>
<volume>8</volume>, <elocation-id>e17</elocation-id>.</mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Jeon</surname><given-names>SG</given-names></name>, <name><surname>Kayama</surname><given-names>H</given-names></name>, <name><surname>Ueda</surname><given-names>Y</given-names></name>, <etal/> (<year>2012</year>) <article-title>Probiotic <italic>Bifidobacterium
breve</italic> induces IL-10-producing Tr1 cells in the colon</article-title>.
<source>PLoS Pathog</source>
<volume>8</volume>, <elocation-id>e17</elocation-id>.</mixed-citation></ref></ref-list></back></article>